ARHGAP26 and infection: Importantly, we found significant resistance to oxaliplatin and 5-fluorouracil after introduction of CLDN18-ARHGAP26 in vitro with different infection systems (Supplementary Fig. 13a-d), providing the possible explanation of poor drug response of patients with such fusion.